Simple Linctus Paediatric Sugar Free
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Simple Linctus Paediatric Sugar Free
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Simple Linctus Paediatric Sugar Free: Citric Acid Monohydrate 31.25 mg/5 ml equivalent to 28.57 mg/5 ml Anhydrous Citric Acid
3 PHARMACEUTICAL FORM
Clear Sugar Free Syrup 4. CLINICAL PARTICULARS
4.1. Therapeutic Indications
For the management of a mild non-specific cough.
4.2. Posology and Method of Administration
Children: one or two 5 ml spoonfuls orally 3-4 times daily.
Adults: Not appropriate.
4.3 Contra-Indications
Not known.
4.4 Special warnings and precautions for use
This medicine contains maltitol liquid. Patients with rare hereditary problems of fructose intolerance should not take this medicine
This medicinal product contains small amounts of ethanol (alcohol), less than 100mg per 5ml dose.
Interaction with other medicinal products and other forms of interaction
4.5
None Known
4.6. Pregnancy and Lactation
Not appropriate.
4.7. Effects on Ability to Drive and Use Machines
Not applicable.
4.8 Undesirable effects
Not Applicable
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard
4.9. Overdose
Sufficient prolonged overdose of citric acid may cause erosion of the teeth and have a local irritant action.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Absorption: Citric Acid Monohydrate is absorbed after oral administration.
Distribution: Citric Acid is found naturally in the body and is widely distributed, about 70% of the citric acid in the body is in hard bone and this accounts for 1.5% of bone content.
Metabolic Reactions: It is an important intermediate in carbohydrate metabolism and its major role is in the tricarboxylic acid cycle (Krebs citric acid cycle); it is metabolised to carbon dioxide and water.
Excretion: Citric acid is normally excreted in the urine in amounts ranging from 0.4 to 1.5g daily and this amount is not increased unless very large doses are administered. The urinary excretion of citric acid is increased in alkaline urine.
5.2. Pharmacokinetic Properties
Not applicable.
5.3. Pre-clinical Safety Data
None stated.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients(per 5ml)
Glycerol (E422)
Sodium Carboxymethylcellulose Sodium Benzoate (E211)
Saccharin Sodium (E954)
Maltitol liquid (E965)
Ethanol (96%)
Star Anise Oil Purified Water
6.2. Incompatibilities
Not appropriate.
6.3. Shelf Life
2 years.
6.4 Special precautions for storage
Store below 25oC
6.5. Nature and Contents of Container
Amber glass bottles with pilfer screw closure.
High density Polyethylene with screw on closure.
Pack sizes of 100 ml, 125 ml, 200 ml for Amber Glass Bottles.
Pack size of 2000 ml for High Density Polyethylene dispensary pack.
6.6. Instructions for Use/Handling
As with all medicines.
7 MARKETING AUTHORISATION HOLDER
Pinewood Laboratories Limited
Ballymacarbry
Clonmel
Co Tipperary
8. MARKETING AUTHORISATION NUMBER(S)
PL 04917/0007
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
17/03/2003
10 DATE OF REVISION OF THE TEXT
13/10/2015